Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Overview

Journal J Pers Med

Date 2021 Mar 6

PMID 33672659

Citations 30

Authors

Patricia Mondelo-Macia

Patricia Castro-Santos

Adrian Castillo-Garcia

Laura Muinelo-Romay

Roberto Diaz-Pena

Affiliations

Soon will be listed here.

Abstract

Liquid biopsies can be used to analyse tissue-derived information, including cell-free DNA (cfDNA), circulating rare cells, and circulating extracellular vesicles in the blood or other bodily fluids, representing a new way to guide therapeutic decisions in cancer. Among the new challenges of liquid biopsy, we found clinical application in nontumour pathologies, including autoimmune diseases. Since the discovery of the presence of high levels of cfDNA in patients with systemic lupus erythaematosus (SLE) in the 1960s, cfDNA research in autoimmune diseases has mainly focused on the overall quantification of cfDNA and its association with disease activity. However, with technological advancements and the increasing understanding of the role of DNA sensing receptors in inflammation and autoimmunity, interest in cfDNA and autoimmune diseases has not expanded until recently. In this review, we provide an overview of the basic biology of cfDNA in the context of autoimmune diseases as a biomarker of disease activity, progression, and prediction of the treatment response. We discuss and integrate available information about these important aspects.

Citing Articles

Circulating cell-free DNA as a potential biomarker for prediction of disease activity and prognosis among Egyptian rheumatoid arthritis patients.

Taha S, Samaan S, Hawash S, El-Sehsah E, Shamloul S, Elsheikh D Int J Immunopathol Pharmacol. 2025; 39:3946320251315036.

PMID: 39891356 PMC: 11786270. DOI: 10.1177/03946320251315036.

Cell-free DNA release following psychosocial and physical stress in women and men.

Limberg A, Berg F, Koper E, Lindgraf C, Gevers C, Kumsta R Transl Psychiatry. 2025; 15(1):26.

PMID: 39863589 PMC: 11763022. DOI: 10.1038/s41398-025-03242-5.

Plasma cell-free DNA as predictor of disease status in patients with differentiated thyroid cancer - a prospective study from a tertiary care institution.

Goel R, Satapathy S, Chandekar K, Ballal S, Agarwal S, Deo S Front Oncol. 2024; 14:1473262.

PMID: 39512775 PMC: 11540813. DOI: 10.3389/fonc.2024.1473262.

Associations between prenatal distress, mitochondrial health, and gestational age: findings from two pregnancy studies in the USA and Turkey.

Huang Q, Shire D, Hollis F, Abuaish S, Picard M, Monk C bioRxiv. 2024; .

PMID: 39464008 PMC: 11507865. DOI: 10.1101/2024.10.16.618719.

MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing.

Passemiers A, Tuveri S, Sudhakaran D, Jatsenko T, Laga T, Punie K Bioinformatics. 2024; 40(9).

PMID: 39177091 PMC: 11379469. DOI: 10.1093/bioinformatics/btae522.

References

Gutierrez-Arcelus M, Rich S, Raychaudhuri S . Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat Rev Genet. 2016; 17(3):160-74. PMC: 4896831. DOI: 10.1038/nrg.2015.33. View

Davis Jr G, Davis 4th J . Detection of circulating DNA by counterimmunoelectrophoresis (CIE). Arthritis Rheum. 1973; 16(1):52-8. DOI: 10.1002/art.1780160108. View

Thierry A, El Messaoudi S, Gahan P, Anker P, Stroun M . Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016; 35(3):347-76. PMC: 5035665. DOI: 10.1007/s10555-016-9629-x. View

Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W . CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol. 2002; 32(7):2084-92. DOI: 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q. View

Rolfo C, Cardona A, Cristofanilli M, Paz-Ares L, Diaz Mochon J, Duran I . Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020; 151:102978. DOI: 10.1016/j.critrevonc.2020.102978. View

Muller S, Dieker J, Tincani A, Meroni P . Pathogenic anti-nucleosome antibodies. Lupus. 2008; 17(5):431-6. DOI: 10.1177/0961203308090030. View

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

Raptis L, Menard H . Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest. 1980; 66(6):1391-9. PMC: 371625. DOI: 10.1172/JCI109992. View

10.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

11.

Shoenfeld Y, Selmi C, Zimlichman E, Gershwin M . The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun. 2008; 31(4):325-30. DOI: 10.1016/j.jaut.2008.08.004. View

12.

Birkelund S, Bennike T, Kastaniegaard K, Lausen M, Poulsen T, Kragstrup T . Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients. Clin Proteomics. 2020; 17:29. PMC: 7412817. DOI: 10.1186/s12014-020-09292-9. View

13.

Rykova E, Sizikov A, Roggenbuck D, Antonenko O, Bryzgalov L, Morozkin E . Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther. 2017; 19(1):85. PMC: 5414163. DOI: 10.1186/s13075-017-1295-z. View

14.

Stearns N, Lee J, Leong K, Sullenger B, Pisetsky D . The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers. PLoS One. 2012; 7(7):e40862. PMC: 3394750. DOI: 10.1371/journal.pone.0040862. View

15.

Hashimoto T, Yoshida K, Hashimoto N, Nakai A, Kaneshiro K, Suzuki K . Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis. Int J Rheum Dis. 2016; 20(6):722-730. DOI: 10.1111/1756-185X.12959. View

16.

Dunaeva M, Derksen M, Pruijn G . LINE-1 Hypermethylation in Serum Cell-Free DNA of Relapsing Remitting Multiple Sclerosis Patients. Mol Neurobiol. 2017; 55(6):4681-4688. PMC: 5948235. DOI: 10.1007/s12035-017-0679-z. View

17.

Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Farinas S, Blasco A . Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017; 17(3):209-215. DOI: 10.1080/14737159.2017.1288568. View

18.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

19.

Steinman C . Circulating DNA in systemic lupus erythematosus. Association with central nervous system involvement and systemic vasculitis. Am J Med. 1979; 67(3):429-35. DOI: 10.1016/0002-9343(79)90789-7. View

20.

Laukova L, Konecna B, Babickova J, Wagnerova A, Meliskova V, Vlkova B . Exogenous deoxyribonuclease has a protective effect in a mouse model of sepsis. Biomed Pharmacother. 2017; 93:8-16. DOI: 10.1016/j.biopha.2017.06.009. View